Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Veracity Capital LLC

Veracity Capital LLC cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,122 shares of the biopharmaceutical company’s stock after selling 241 shares during the quarter. Regeneron Pharmaceuticals accounts for about 2.3% of Veracity Capital LLC’s portfolio, making the stock its 7th largest holding. Veracity Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $5,892,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in REGN. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $932,571,000. International Assets Investment Management LLC raised its position in shares of Regeneron Pharmaceuticals by 76,169.5% in the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after buying an additional 590,314 shares in the last quarter. Global Assets Advisory LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $339,594,000. First Trust Advisors LP raised its position in shares of Regeneron Pharmaceuticals by 115.2% in the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after buying an additional 195,902 shares in the last quarter. Finally, abrdn plc grew its holdings in shares of Regeneron Pharmaceuticals by 552.8% during the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after purchasing an additional 186,215 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on REGN shares. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target on the stock. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. JPMorgan Chase & Co. lifted their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Monday, June 17th. Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Finally, Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,027.55.

Regeneron Pharmaceuticals Trading Down 2.0 %

Shares of NASDAQ:REGN traded down $20.57 during trading on Thursday, reaching $1,024.09. The stock had a trading volume of 378,341 shares, compared to its average volume of 459,242. The firm’s fifty day moving average is $992.50 and its 200 day moving average is $954.60. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. Regeneron Pharmaceuticals, Inc. has a 52 week low of $688.52 and a 52 week high of $1,081.17. The stock has a market cap of $112.84 billion, a price-to-earnings ratio of 30.25, a P/E/G ratio of 2.16 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,467,684. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the transaction, the director now owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Michael S. Brown sold 1,172 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Insiders have sold 63,208 shares of company stock worth $62,514,142 in the last quarter. Company insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.